November 29, 2022
Life Sciences
  • Research published in JAMA Internal Medicine revealed that Food and Drug Administration (FDA) approvals of “skinny labels” on biosimilars saved Medicare over $1 billion over five years. According to the research, the FDA approved 33 biosimilars based on 11 biologics between 2015 and 2021, two-thirds of which had a skinny label. The researchers estimate competition from skinny-label biosimilars saved Medicare $1.5 billion from 2015 to 2020 due to years of earlier competition – nearly 5 percent of the $30.2 billion Medicare spent on the five biologics during that period. (Research letter here; Article here)